Theravance Biopharma's CYPRESS Phase 3 study for ampreloxetine failed to meet its primary endpoint in treating symptomatic neurogenic orthostatic hypotension (nOH), leading to program termination. 1 2 4 Company announced 50% workforce reduction, complete wind-down of R&D organization, and ~50% cut in G&A employees, to be implemented over next two quarters. 1 2 3 4 Restructuring aims to reduce operating expenses by ~60%, saving ~$70 million through Q3 2026, with one-time severance costs of $5-7 million. 1 3 4 Despite setbacks, expects global net sales of at least $3.51 billion in 2026 from YUPELRI for COPD. 1 Stock plunged nearly 30% to $13.82 post-announcement, breaking below 200-day moving average. 1 Sources: 1. https://intellectia.ai/news/stock/theravance-biopharma-cuts-workforce-by-50-amid-phase-3-trial-failure 2. https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2026 3. https://www.marketscreener.com/news/theravance-biopharma-inc-plans-...
- Get link
- X
- Other Apps